ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.24 USD -1.81% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

ACADIA Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ACADIA Pharmaceuticals Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Revenue
$929.2m
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

ACADIA Pharmaceuticals Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

ACAD Intrinsic Value
19.92 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is ACADIA Pharmaceuticals Inc's Revenue?
Revenue
929.2m USD

Based on the financial report for Sep 30, 2024, ACADIA Pharmaceuticals Inc's Revenue amounts to 929.2m USD.

What is ACADIA Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
25%

Over the last year, the Revenue growth was 47%. The average annual Revenue growth rates for ACADIA Pharmaceuticals Inc have been 25% over the past three years , 25% over the past five years .

Back to Top